All Relations between asymmetrical (pato 0000616) and nitrogen monoxide

Reference Sentence Publish Date Extraction Date Species
Stefan Pilz, Frank Edelmann, Andreas Meinitzer, G\\xc3\\xb6tz Gelbrich, Ufuk D\\xc3\\xb6ner, Hans-Dirk D\\xc3\\xbcngen, Andreas Tomaschitz, Katharina Kienreich, Martin Gaksch, Andr\\xc3\\xa9 Duvinage, Raoul Stahrenberg, Jan Kunde, Albrecht Schmidt, Winfried M\\xc3\\xa4rz, Rolf Wachter, Burkert Piesk. Associations of methylarginines and homoarginine with diastolic dysfunction and cardiovascular risk factors in patients with preserved left ventricular ejection fraction. Journal of cardiac failure vol 20 issue 12 2015 25230239 asymmetric dimethylarginine (adma), symmetric dimethylarginine (sdma), and homoarginine are considered to modulate nitric oxide synthesis. 2015-07-23 2022-01-12 Not clear
Meltem Ercan, Sinem Firtina, Dildar Konukogl. Comparison of plasma viscosity as a marker of endothelial dysfunction with nitric oxide and asymmetric dimethylarginine in subjects with dyslipidemia. Clinical hemorheology and microcirculation vol 57 issue 4 2015 23455843 comparison of plasma viscosity as a marker of endothelial dysfunction with nitric oxide and asymmetric dimethylarginine in subjects with dyslipidemia. 2015-07-08 2022-01-12 Not clear
Meltem Ercan, Sinem Firtina, Dildar Konukogl. Comparison of plasma viscosity as a marker of endothelial dysfunction with nitric oxide and asymmetric dimethylarginine in subjects with dyslipidemia. Clinical hemorheology and microcirculation vol 57 issue 4 2015 23455843 in this study, we aimed to investigate the alterations in plasma viscosity and whether there was a relationship between plasma viscosity and endothelial dysfunction markers such as nitric oxide (nox), asymmetric dimethylarginine (adma) and oxidized low density lipoprotein (oxldl) in dyslipidemic subjects. 2015-07-08 2022-01-12 Not clear
Shufen Chen, Na Li, Milani Deb-Chatterji, Qiang Dong, Jan T Kielstein, Karin Weissenborn, Hans Worthman. Asymmetric dimethyarginine as marker and mediator in ischemic stroke. International journal of molecular sciences vol 13 issue 12 2015 23443106 asymmetric dimethylarginine (adma), an endogenous nitric oxide synthase (nos) inhibitor, is known as mediator of endothelial cell dysfunction and atherosclerosis. 2015-07-03 2022-01-12 Not clear
Ji-Peng Zhou, Yong-Ping Bai, Xiao-Lei Hu, Da-Bin Kuang, Rui-Zheng Shi, Yan Xiong, Wei Zhang, Jian Xia, Bi-Lian Chen, Tian-Lun Yang, Xiao-Ping Che. Association of the AGXT2 V140I polymorphism with risk for coronary heart disease in a Chinese population. Journal of atherosclerosis and thrombosis vol 21 issue 10 2015 24834905 asymmetric dimethylarginine (adma) is a nitric oxide synthase (nos) inhibitor that decreases no production and promotes the development of cardiovascular diseases. 2015-07-02 2022-01-12 Not clear
Francesca Romana Spinelli, Manuela Di Franco, Alessio Metere, Fabrizio Conti, Cristina Iannuccelli, Luciano Agati, Guido Valesin. Decrease of asymmetric dimethyl arginine after anti-TNF therapy in patients with rheumatoid arthritis. Drug development research vol 75 Suppl 1 issue 2015 25381982 asymmetric dimethyl arginine (adma), an endogenous inhibitor of nitric oxide synthase, contributes to the impairment of endothelial function, the earlier and reversible stage of atherosclerotic plaque formation. 2015-07-01 2022-01-12 Not clear
James M Roberts, Lisa M Bodnar, Thelma E Patrick, Robert W Power. The Role of Obesity in Preeclampsia. Pregnancy hypertension vol 1 issue 1 2015 21532964 we further address the hypothesis that asymmetric dimethyl arginine (adma), an endogenous inhibitor of nitric oxide synthase, may be one convergence point for the mechanism by which obesity increases the risk of preeclampsia. 2015-06-25 2022-01-12 Not clear
R Powers, J Gefte. OS075. Endothelial-dependent vascular function is significantly impaired in obesity and restored by overexpression of DDAH1: Evidence for the role of ADMA. Pregnancy hypertension vol 2 issue 3 2015 26105289 asymmetric dimethylarginine (adma) is an endogenous inhibitor of nitric oxide synthase and metabolized primarily by the enzyme ddah1. 2015-06-25 2022-01-12 Not clear
Ozge Tugce Pasaoglu, Nurten Turkozkan, Mustafa Ark, Belgin Polat, Mehmet Agilli, Halil Yama. The effect of taurine on the relationship between NO, ADMA and homocysteine in endotoxin-mediated inflammation in HUVEC cultures. Inflammation vol 37 issue 5 2015 24604342 the aim of our study was to investigate the effect of taurine on the relationship between nitric oxide (no), asymmetric dimethylarginine (adma) and homocysteine (hcy) in endotoxin-induced human umblical vein endothelial cell (huvec) cultures. 2015-06-22 2022-01-12 Not clear
Fernanda Genre, Raquel L\\xc3\\xb3pez-Mej\\xc3\\xadas, Javier Rueda-Gotor, Jos\\xc3\\xa9 A Miranda-Filloy, Bego\\xc3\\xb1a Ubilla, Aurelia Villar-Bonet, Beatriz Carnero-L\\xc3\\xb3pez, In\\xc3\\xa9s G\\xc3\\xb3mez-Acebo, Ricardo Blanco, Trinitario Pina, Carlos Gonz\\xc3\\xa1lez-Juanatey, Javier Llorca, Miguel A Gonz\\xc3\\xa1lez-Ga. IGF-1 and ADMA levels are inversely correlated in nondiabetic ankylosing spondylitis patients undergoing anti-TNF-alpha therapy. BioMed research international vol 2014 issue 2015 25295265 although no association of igf-1 and igfbp-3 levels with angiopoietin-2 or osteopontin was found, an inverse correlation between igf-1 levels and asymmetric dimethylarginine (adma), an endogenous endothelial nitric oxide synthase inhibitor that impairs nitric oxide production and secretion promoting endothelial dysfunction, was found (r=-0.397; p=0.04). 2015-06-11 2022-01-12 Not clear
Mohammad Badran, Saeid Golbidi, Najib Ayas, Ismail Lahe. Nitric Oxide Bioavailability in Obstructive Sleep Apnea: Interplay of Asymmetric Dimethylarginine and Free Radicals. Sleep disorders vol 2015 issue 2015 26064689 nitric oxide bioavailability in obstructive sleep apnea: interplay of asymmetric dimethylarginine and free radicals. 2015-06-11 2022-01-12 Not clear
Andrea Ferrigno, Vittoria Rizzo, Alberto Bianchi, Laura G Di Pasqua, Clarissa Berardo, Plinio Richelmi, Mariapia Vairett. Changes in ADMA/DDAH pathway after hepatic ischemia/reperfusion injury in rats: the role of bile. BioMed research international vol 2014 issue 2015 25243167 we investigated the effects of hepatic ischemia/reperfusion (i/r) injury on asymmetric dimethylarginine (adma, a nitric oxide synthase inhibitor), protein methyltransferase (prmt) and dimethylarginine dimethylaminohydrolase (ddah) (involved, resp., in adma synthesis and degradation), and the cationic transporter (cat). 2015-06-04 2022-01-12 Not clear
Feng Xu, Yaning Sun, Rui Shang, Minghua Li, Lianqun Cui, Zhaoqiang Cui, Yuguo Che. The Glu504Lys polymorphism of aldehyde dehydrogenase 2 contributes to development of coronary artery disease. The Tohoku journal of experimental medicine vol 234 issue 2 2015 25263942 several studies have suggested that aldh2 polymorphism plays an important role in the progress of cad through multiple mechanisms, including the regulation of alcohol consumption, inflammation, endothelial progenitor cells, oxidative stress, asymmetric dimethylarginine, endothelial nitric oxide synthase, and other cad-promoting factors. 2015-05-20 2022-01-12 Not clear
Hiroyuki Konya, Masayuki Miuchi, Kahori Satani, Satoshi Matsutani, Yuzo Yano, Taku Tsunoda, Takashi Ikawa, Toshihiro Matsuo, Fumihiro Ochi, Yoshiki Kusunoki, Masaru Tokuda, Tomoyuki Katsuno, Tomoya Hamaguchi, Jun-Ichiro Miyagawa, Mitsuyoshi Namb. Asymmetric dimethylarginine, a biomarker of cardiovascular complications in diabetes mellitus. World journal of experimental medicine vol 5 issue 2 2015 25992325 from another point of view, asymmetric dimethylarginine (adma) has been established as an inhibitor of endogenous nitric oxide synthesis and the relationship between adma and arteriosclerosis has been reported. 2015-05-20 2022-01-12 Not clear
Zaiming Luo, Shakil Aslam, William J Welch, Christopher S Wilco. Activation of nuclear factor erythroid 2-related factor 2 coordinates dimethylarginine dimethylaminohydrolase/PPAR-\\xce\\xb3/endothelial nitric oxide synthase pathways that enhance nitric oxide generation in human glomerular endothelial cells. Hypertension (Dallas, Tex. : 1979) vol 65 issue 4 2015 25691623 dimethylarginine dimethylaminohydrolase (ddah) degrades asymmetric dimethylarginine, which inhibits nitric oxide (no) synthase (nos). 2015-05-12 2022-01-12 Not clear
Carlee D Schultz, Geetanjali Rangneker, Han S Lim, Angelique Fraudeau, Glenn Young, Kurt Roberts-Thomson, Bobby John, Matthew Worthley, Prashanthan Sanders, Scott R Willoughb. Characterization of thrombogenic, endothelial and inflammatory markers in supraventricular tachycardia: a study in patients with structurally normal hearts. Clinical and experimental pharmacology & physiology vol 41 issue 8 2015 24827644 between peripheral and atrial sample sites, patients with svt showed no change in platelet reactivity or aggregation (p-selectin (cd62p) p\xc2\xa0=\xc2\xa00.91; platelet-derived soluble cd40 ligand p\xc2\xa0=\xc2\xa00.9), thrombus formation (thrombin-antithrombin complex; p\xc2\xa0=\xc2\xa00.55), endothelial function (von willebrand factor p\xc2\xa0=\xc2\xa00.75; asymmetric dimethylarginine (adma) p\xc2\xa0=\xc2\xa00.97; nitric oxide p\xc2\xa0=\xc2\xa00.61), or inflammation (vascular cell adhesion molecule-1 p\xc2\xa0=\xc2\xa00.59; intercellular adhesion molecule-1 (icam-1) p\xc2\xa0=\xc2\xa00.69). 2015-05-11 2022-01-12 Not clear
Muyesser Sayki Arslan, Sibel Turhan, Irem Dincer, Dilsa Mizrak, Demet Corapcioglu, Ramazan Idilma. A potential link between endothelial function, cardiovascular risk, and metabolic syndrome in patients with Non-alcoholic fatty liver disease. Diabetology & metabolic syndrome vol 6 issue 2015 25960770 asymmetric dimethylarginine (adma) is an endogenous competitive inhibitor of nitric oxide (no) synthetase. 2015-05-11 2022-01-12 Not clear
David A Drew, Hocine Tighiouart, Tammy Scott, Amy Kantor, Li Fan, Carlo Artusi, Mario Plebani, Daniel E Weiner, Mark J Sarna. Asymmetric dimethylarginine, race, and mortality in hemodialysis patients. Clinical journal of the American Society of Nephrology : CJASN vol 9 issue 8 2015 24970872 levels of asymmetric dimethylarginine, an inhibitor of nitric oxide synthase, are elevated in kidney disease and associated with mortality in white european hemodialysis populations. 2015-04-24 2022-01-12 Not clear
Li-Tung Huang, Chih-Sung Hsieh, Kow-Aung Chang, You-Lin Tai. Roles of nitric oxide and asymmetric dimethylarginine in pregnancy and fetal programming. International journal of molecular sciences vol 13 issue 11 2015 23203083 roles of nitric oxide and asymmetric dimethylarginine in pregnancy and fetal programming. 2015-04-23 2022-01-12 Not clear
Theodoros Dimitroulas, Aamer Sandoo, George D Kita. Asymmetric dimethylarginine as a surrogate marker of endothelial dysfunction and cardiovascular risk in patients with systemic rheumatic diseases. International journal of molecular sciences vol 13 issue 10 2015 23202900 asymmetric dimethylarginine (adma) is one of the most potent endogenous inhibitors of the three isoforms of nitric oxide synthase and it is a newly discovered risk factor in the setting of diseases associated with endothelial dysfunction and adverse cardiovascular events. 2015-04-21 2022-01-12 Not clear
Page: 
1   2   3   4   5   6   7   8   9   10   11   12   13   14   15   16   17   18   19   20   21   22   23   24   25   26   27   28   29   30   31   32   33   34   35   36   37   38   39   40   41   42   43   44   45   46   47   48   49   50   51   52   53   54